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Explosivity:		
An	unusual	challenge	in	drug	development	
INTRODUCTION 
 
There remains an urgent global need for new 
drugs to combat diseases such as malaria, 
tuberculosis and cancer, as well as overcoming 
increasing antibiotic resistance. Chemists are 
moving into Ônew chemical spaceÕ for drug 
design (1,2) and with this comes the possibility 
of traditional (and stable) Ôcarbon-carbonÕ bond 
structures being replaced by more ÔexoticÕ 
bonding arrangements.  While the implication 
of this on pharmaceutical stability can often be 
mitigated by suitable formulation and storage 
strategies, we came across an unusual case of 
chemical stability: the possibility that the drug 
was an explosive! By pushing drug designing 
into uncharted chemical space it could be 
argued that the possibility of finding explosive 
molecules of pharmaceutical interest will 
increase. 
In this short paper we discuss the implications 
of a molecule found to require formal 
explosivity testing and the impact on the 
development of a clinical product.  
	
EXPLOSIVITY TESTING 
	
Formal explosivity testing can take a variety of 
forms. The UN guidance document (3) 
contains a wide array of tests and equipment 
that can be used to determine explosive testing. 
Additionally, negative and positive outcomes 
to the various tests move the testing onto other 
procedures. There is an initial series of tests 
(Test Series 1 to 4) which would apply to 
materials meeting Criteria 1 to 3 above which 
may determine material as Class I. This may be 
followed by a further series of tests much may 
classify the material into subgroups (division 
Group 1.1 to 1.6). These tests determine the 
ability of the material to be handled and 
transported. The tests generally use quantities 
of powder in the range of tens to hundreds of 
grams, and so are considerable undertakings 
for a early phase clinical development 
program. 
 
CASE STUDY 
 
The authors routinely develop novel drug 
candidates for early phases clinical trial, and as 
part of that role received a novel di-N-oxide 
drug compound for scale up synthesis (Onyx 
Scientific) and drug product production.  
 
 
 
 
 
 
 
 
 
CASE STUDY (contÕd) 
  
Routine physico-chemical characterisation 
showed no usual features. However, upon 
review it was discovered that the Ôsharp 
melting pointÕ - which would normally indicate 
high purity material - was incorrectly assigned 
to an endothermic event, and that the material 
demonstrated a strongly exothermic event! 
Occurring at 190ûC, the energy values 
indicated that the compound released upto 
1000 J/g (which compared to gunpowder and 
TNT at 3000 and 4000 J/g, respectively).  
Further study showed that the compound 
matched the three criteria specified above and 
was considered for explosivity testing through 
the Test SeriesÕ specified in reference 3. 
 
Several challenges immediately presented 
themselves: understanding the Test Series and 
finding a commercial provider who could both 
conduct the tests and was able to handle a 
pharmaceutically active anti-cancer compound; 
scaling up the API production so that enough 
material was available to conduct the Test 
Series; handling the tens of grams onsite at the 
formulation production facility uncertain about 
the explosive potential of the material; and 
finally the implication of project timelines.  
 
It took several weeks to find a facility that 
could both handle the material and conduct the 
testing. Initial tests on the Ôtens gramsÕ 
indicated that the material should be processed 
through a formal Test Series 1 requiring 
200-250 grams of material costing in excess of 
£72,000, before showing that the novel drug 
was not explosive and could be handled as a 
normal drug substance. The time between 
observing the strong exothermic decomposition 
and obtaining the final result was over a year. 
While this did not stall the project, all further 
development, scale up and production work 
needed additional considerations to allow for 
the uncertainties over the explosivity issue.  
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MITIGATING RISK IN DRUG DESIGN 
 
The identification of relevant groups using the 
flow chart above can easily performed at the drug 
design stage, before any material is synthesised. 
Materials that match the criteria could be 
synthesised and then assessed by differential 
scanning calorimetry (which would only require a 
few milligrams).  
Rather than the formal explosivity testing it 
would be highly desirable, in light of the new 
chemical bonding arrangements that may appear 
in the future, to determine a set of small scale 
tests (milligram to gram) which could establish 
the risk presented by a potentially ÔexplosiveÕ new 
chemical entity. This could be used during early 
clinical development, leaving formal and costly 
UN Test Series experiments until the larger scale 
production required for later clinical stages. 
Flowchart to determine if formal explosivity testing 
might be required.	
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Criteria	1:	Does	the	compound	contain	any	of	the	
following	func=onal	groups?	C-C	unsatura=on	(ie	
acetylenes,	acetylides,	dienes),	C/N-metal	bonds	(ie	
organo-lithium),	con=guous	N/O	atoms	(ie	peroxides,	
azides,	azo	compounds),	N-O	bonds	(ie	N-oxides,	
nitro,	nitroso	compounds)	or	N/O-halogen	bonds	(ie	
haloamides).	
Yes	 No	 Stop	
Criteria	2:	Molecules	where	the	oxygen	balance	is	
less	than	-200	calculated	by	the	following	equa=on.	
	
Oxygen	Balance=	-1600	x	(2x+(y/2)-z)/mwt	
	
where	x,y	and	z	are	CxHyOz	
Yes	 No	 Stop	
Criteria	3:	The	onset	of	exothermic	decomposi=on	is	
<500˚C	and	releases	more	than	500J/g.	
Yes	 No	 Stop	
Class	I	material	tes=ng	required.	
